WO2005049142A2 - Graduated estrogen contraceptive - Google Patents
Graduated estrogen contraceptive Download PDFInfo
- Publication number
- WO2005049142A2 WO2005049142A2 PCT/US2004/037975 US2004037975W WO2005049142A2 WO 2005049142 A2 WO2005049142 A2 WO 2005049142A2 US 2004037975 W US2004037975 W US 2004037975W WO 2005049142 A2 WO2005049142 A2 WO 2005049142A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- ethinyl estradiol
- phase
- meg
- norethindrone acetate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Definitions
- This invention is directed to a method of contraception that provides for the reduction or elimination of estrogen in the initial phase of a multiphasic estrogenic/progestogenic contraceptive regimen without compromising contraceptive efficacy or cycle control.
- the invention is also directed to a multiphase contraceptive kit that may be used to practice the method of the invention.
- Contraceptive compositions containing both estrogenic and progestogemc compounds are well known.
- the progestogemc component of the composition is primarily responsible for the contraceptive efficacy of the composition, while the estrogenic component is employed to reduce undesired side effects, such as breakthrough bleeding or spotting.
- the earliest of these estrogenic/progestogenic contraceptive compositions contained a relatively high level of estrogenic component.
- a constant goal has been to reduce the estrogenic potency of such compositions without reducing contraceptive efficacy and increasing undesired side effects.
- numerous regimens have been developed in which the progestin/estrogen combination is administered in a monophasic regimen (fixed dose) or as biphasic or triphasic regimens (varied dose).
- a particularly advantageous technique for reducing total estrogenic administration is described in U.S. Patent No. 4,962,098.
- This describes a triphasic method of contraception using a progestogen estrogen combination in which the amount of estrogen is increased stepwise over the three phases.
- the first phase is 4-7 days
- the second phase is 5-8 days
- the third phase is 7-12 days.
- the administration of the contraceptive compositions for the three phases will be 21 days followed by a 7 day placebo period.
- the progesten is 0.5 to 1.5 g of norethindrone acetate, while about 10 to 30 meg of ethinyl estradiol is used in the first phase, about 20 to 40 meg of ethinyl estradiol is used in the second phase and 30 to 50 meg of ethinyl estradiol is employed in the third phase.
- the progesten is 0.5 to 1.5 g of norethindrone acetate, while about 10 to 30 meg of ethinyl estradiol is used in the first phase, about 20 to 40 meg of ethinyl estradiol is used in the second phase and 30 to 50 meg of ethinyl estradiol is employed in the third phase.
- compositions I, ⁇ and HI all contain a progestogen in an amount equivalent to about 0.3 to about 1.5 mg, preferably about 0.5 to about 1.5 mg of norethindrone acetate.
- Composition I contains an estrogen in an amount equivalent to about 0 to less than about 10 meg of ethinyl estradiol and both compositions II and HI contain an estrogen in an amount equivalent to about 10 to about 50 meg of ethinyl estradiol.
- the sequential administration of compositions I, ⁇ and 1TJ is repeated after a period of about 1 to about 4 days has elapsed after completion of the administration of composition EL
- this relatively short interim period between the sequential administration of the estrogenic/progestogenic components allows for the advantageous reduction or elimination of estrogen from the first phase of the above-described triphasic regimen without compromising efficacy or cycle control.
- the amount of estrogen be increased by at least an amount equivalent to 5 meg of ethinyl estradiol between composition II and composition EL
- the estrogen is ethinyl estradiol and the progestogen is norethindrone acetate.
- Yet another embodiment of this invention is directed to a multiphase combination and contraceptive kit comprising a package containing daily dosages of: (a) a Phase I composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg, preferably about 0.5 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 0 to about 10 meg of ethinyl estradiol; (b) a Phase ⁇ composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg, preferably about 0.5 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 10 to about 50 meg of ethinyl estradiol; and (c) a Phase HI composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg, preferably about 0.5 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 10 to about 50 meg of ethiny
- the method of this invention is practiced by administration of the compositions in a numeric sequence with the Phase I composition being used first, the Phase II composition being used second, etc. If packaging and/or other requirements dictate, the method and kit described herein can be employed as part of a larger scheme for contraception or treatment of gynecological disorders. While the sequence in which Applicant's combinations are administered is important to their operation, it should be kept in mind that variations in timing and dosage can be tolerated when medical considerations so dictate.
- the method of this invention provides that the sequential administration of compositions I, ⁇ and m is repeated after a period of about 1 to about 4 days has elapsed after the completion of the administration of composition m. More preferably, the number of days between the completion of the administration of composition III and beginning the repeated sequential administration of compositions I, TJ and ITJ is from about 2 to about 4 days.
- an iron supplement and/or a placebo may be preferably administered on a daily basis, although there is no requirement for the administration of anything during this interim period, i.e., the period between the completion of the prior sequential administration of compositions I-HI and the start of the next sequential administration of compositions I-m.
- Estrogens which may be used in the present invention include, for example, ethinyl estradiol, 17 ⁇ -estradiol, 17 ⁇ -estradiol-3 -acetate, mestranol, conjugated estrogens, USP and estrone or salts thereof.
- the amount of estrogen used is described herein as that which is "equivalent" in estrogenic potency to an amount of ethinyl estradiol.
- the equivalent estrogenic potency of an estrogen to ethinyl estradiol may be readily determined by one of ordinary skill in the art. It is contemplated that each Phase could employ one or more different estrogens that deliver a potency equivalent to the recited amount of ethinyl estradiol.
- the estrogen used in one Phase may be different than that used in another Phase.
- the estrogen for each Phase if present, is ethinyl estradiol.
- Progestogens which may be used in the present invention include, for example, progesterone and its derivatives such as 17-hydroxy progesterone esters and 19-nor-17-hydroxy progesterone esters, 17-alpha-ethinyl testosterone, 17-alpha- ethinyl-19-nortestosterone (norethindrone) and derivatives thereof, norethindrone acetate, norgestrel, nogestamate, desogestrel and D-17-beta-acetoxy-17-beta-ethyl- 17-alpha-ethinyl-gon-4-en-3-one oxime.
- progestogens include demegestone, drospirenone, dydrogesterone, gestodene, medrogestone, medroxy progesterone and esters thereof.
- the amount of progestogen used is described herein as that which is "equivalent" in progestogemc potency to an amount of norethindrone acetate.
- the equivalent progestogemc potency of a progestogen to norethindrone acetate may be readily determined by one of ordinary skill in the art. It is contemplated that each Phase could employ one or more different progestogens that deliver a potency equivalent to the recited amount of norethindrone acetate. It is also contemplated that the progestogen used in one Phase may be different than that used in another Phase. In a most preferred embodiment of this invention, however, the progestogen for each Phase is norethindrone acetate.
- compositions employed in accordance with the invention will contain in Phase I about 0.3-1.5 mg, preferably about 0.5-1.5 mg norethindrone acetate and about 0 to less than about 10 meg ethinyl estradiol, preferably about 0 to about 5 meg ethinyl estradiol, in Phase II about 0.3-1.5 mg, preferably about 0.5-1.5 mg norethindrone acetate and about 10- 50 meg ethinyl estradiol, preferably about 20-40 meg ethinyl estradiol, and in Phase in about 0.3-1.5 mg, preferably about 0.5-1.5 mg norethindrone acetate and about 10-50 meg ethinyl estradiol, preferably about 25-50 meg ethinyl estradiol, wherein the amount of ethinyl estradiol is increased by at least 5 meg from Phase TJ to Phase m
- the Phase I composition has a significantly lower concentration of estrogen equivalent to ethinyl estradiol than previously considered possible, while maintaining contraceptive efficacy and avoiding or minimizing unwanted side effects such as break through bleeding.
- the amount of estrogen equivalent to ethinyl estradiol in the Phase I composition is about 5 meg.
- the Phase I composition is substantially free of estrogen, and most preferably is substantially free of ethinyl estradiol.
- substantially free means that estrogen is not detectable or only pharmacologically insignificant minor levels are present.
- An optional Phase IV composition which contains an iron supplement, e.g., ferrous fumarate, and/or one or more placebos, can be used in conjunction with the other three.
- an iron supplement e.g., ferrous fumarate, and/or one or more placebos
- compositions employed in accordance with the invention in. Phases I through TV will more preferably have the administration times and drug contents set forth in the following tables when a four-phase system is used. Each table sets forth relevant values for one of Applicant's preferred embodiments, or configurations, for administration of the system to females. Table 1
- NA norethindrone acetate
- EE ethinyl estradiol
- compositions used in this invention are administered using a suitable daily dosage form. Tablets, pills, capsules and caplets are exemplary dosage forms.
- other conventional additives e.g., fillers, colorants, polymeric binders, and the like is also contemplated. In general any pharmaceutically-acceptable additive which does not interfere with the function of the active components can be used in one or more of the compositions.
- Suitable carriers with which the compositions can be administered include lactose, starch, cellulose derivatives and the like used in suitable amounts. Lactose is a preferred carrier. Mixtures of carriers, e.g. lactose, microcrystalline cellulose and starch, are operable.
- norethindrone acetate is preferred, as previously noted it may be replaced by a different progestogen.
- ethinyl estradiol component is preferred it may be completely or partially replaced with one or more conventional estrogenic substances, e.g., mestranol.
- Phase IV is not essential to the operation of the other three distinct phases.
- a method or kit which does not contain the Phase IV component is operable and, in fact, will be preferred when suitable factors, e.g., economy, dictate the non-use of the Phase TV component.
- suitable factors e.g., economy, dictate the non-use of the Phase TV component.
- whether a Phase IV component is used or not it is preferably that the period between the completion of the Phase ITJ composition and the start of the Phase I composition in the subsequent sequence not exceed about 4 days.
- a unique dosage pattern i.e., a unique sequence of administration of a novel estrogen/progestogen combination has been discovered which minimizes the administration of estrogen in the first phase of a multiphase regimen, while also minimizing certain side effects, notably breakthrough bleeding, commonly associated with conventional low dosage pills.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006539949A JP2007511533A (en) | 2003-11-14 | 2004-11-12 | Staged estrogen contraceptives |
CA2542854A CA2542854C (en) | 2003-11-14 | 2004-11-12 | Graduated estrogen contraceptive |
DE602004017045T DE602004017045D1 (en) | 2003-11-14 | 2004-11-12 | GRADUATED ESTROGEN CONTRAZEPTIVA |
EP04819121A EP1689411B1 (en) | 2003-11-14 | 2004-11-12 | Graduated estrogen contraceptive |
IL174893A IL174893A (en) | 2003-11-14 | 2006-04-10 | Triphasic estrogen contraceptive with low level initial estrogen phase followed by stepped increases in estrogen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52018203P | 2003-11-14 | 2003-11-14 | |
US60/520,182 | 2003-11-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005049142A2 true WO2005049142A2 (en) | 2005-06-02 |
WO2005049142A3 WO2005049142A3 (en) | 2005-09-29 |
Family
ID=34619442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/037975 WO2005049142A2 (en) | 2003-11-14 | 2004-11-12 | Graduated estrogen contraceptive |
Country Status (9)
Country | Link |
---|---|
US (2) | US8124595B2 (en) |
EP (1) | EP1689411B1 (en) |
JP (1) | JP2007511533A (en) |
CN (1) | CN1878558A (en) |
AT (1) | ATE410171T1 (en) |
CA (1) | CA2542854C (en) |
DE (1) | DE602004017045D1 (en) |
IL (1) | IL174893A (en) |
WO (1) | WO2005049142A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007002910A1 (en) * | 2005-06-29 | 2007-01-04 | Warner Chilcott Company, Inc. | Quadraphasic continuous graduated estrogen contraceptive |
WO2007106264A2 (en) * | 2006-03-02 | 2007-09-20 | Warner Chilcott Company, Inc. | Extended cycle multiphasic oral contraceptive method |
WO2009112232A2 (en) * | 2008-03-10 | 2009-09-17 | Vladimir Hanes | New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
US8906890B2 (en) | 2010-04-15 | 2014-12-09 | Bayer Intellectual Property Gmbh | Very low-dosed solid oral dosage forms for HRT |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005092441A2 (en) * | 2004-03-19 | 2005-10-06 | Warner Chilcott Company, Inc. | Extended cycle multiphasic oral contraceptive method |
TW200942242A (en) * | 2008-03-10 | 2009-10-16 | Rolf Schurmann | New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
MX2016014281A (en) | 2014-05-22 | 2017-02-22 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies. |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
US20230135376A1 (en) | 2020-06-25 | 2023-05-04 | Millicent Pharma Limited | Multiphasic contraceptive and/or hormone replacement therapy |
WO2023037264A1 (en) | 2021-09-07 | 2023-03-16 | Millicent Pharma Limited | Contraceptive regimen including reduced level of estrogen |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0253607A1 (en) * | 1986-07-15 | 1988-01-20 | American Home Products Corporation | Combination dosage form for premenopausal women |
US4962098A (en) * | 1987-06-15 | 1990-10-09 | Warner-Lambert Company | Graduated estrogen contraceptive |
DE4313926A1 (en) * | 1993-04-28 | 1994-11-03 | Jenapharm Gmbh | Multiphase pharmaceutical product for hormonal contraception |
US5888543A (en) * | 1996-07-26 | 1999-03-30 | American Home Products Corporation | Oral contraceptives |
US6479475B1 (en) * | 1996-07-26 | 2002-11-12 | Wyeth | Oral contraceptive |
US6511970B1 (en) * | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4292315A (en) * | 1977-12-30 | 1981-09-29 | Nichols Vorys | Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system |
US4921843A (en) * | 1988-10-20 | 1990-05-01 | Pasquale Samuel A | Contraception system and method |
US5552394A (en) * | 1994-07-22 | 1996-09-03 | The Medical College Of Hampton Roads | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
WO2005092441A2 (en) * | 2004-03-19 | 2005-10-06 | Warner Chilcott Company, Inc. | Extended cycle multiphasic oral contraceptive method |
US7704984B2 (en) * | 2005-04-22 | 2010-04-27 | Warner Chilcott Company, Llc | Extended estrogen dosing contraceptive regimen |
US8461138B2 (en) * | 2005-06-29 | 2013-06-11 | Warner Chilcott Company, Llc | Quadraphasis continuous graduated estrogen contraceptive |
US8063030B2 (en) * | 2006-03-02 | 2011-11-22 | Warner Chilcott Company, Llc | Extended cycle multiphasic oral contraceptive method |
-
2004
- 2004-11-12 WO PCT/US2004/037975 patent/WO2005049142A2/en active Application Filing
- 2004-11-12 CN CNA2004800332158A patent/CN1878558A/en active Pending
- 2004-11-12 JP JP2006539949A patent/JP2007511533A/en active Pending
- 2004-11-12 DE DE602004017045T patent/DE602004017045D1/en active Active
- 2004-11-12 CA CA2542854A patent/CA2542854C/en active Active
- 2004-11-12 US US10/987,653 patent/US8124595B2/en active Active
- 2004-11-12 EP EP04819121A patent/EP1689411B1/en active Active
- 2004-11-12 AT AT04819121T patent/ATE410171T1/en not_active IP Right Cessation
-
2006
- 2006-04-10 IL IL174893A patent/IL174893A/en active IP Right Grant
-
2010
- 2010-11-16 US US12/947,397 patent/US9132137B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0253607A1 (en) * | 1986-07-15 | 1988-01-20 | American Home Products Corporation | Combination dosage form for premenopausal women |
US4962098A (en) * | 1987-06-15 | 1990-10-09 | Warner-Lambert Company | Graduated estrogen contraceptive |
DE4313926A1 (en) * | 1993-04-28 | 1994-11-03 | Jenapharm Gmbh | Multiphase pharmaceutical product for hormonal contraception |
US5888543A (en) * | 1996-07-26 | 1999-03-30 | American Home Products Corporation | Oral contraceptives |
US6479475B1 (en) * | 1996-07-26 | 2002-11-12 | Wyeth | Oral contraceptive |
US6511970B1 (en) * | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
Non-Patent Citations (1)
Title |
---|
KAUNITZ A M: "Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa(TM) (desogestrel/ethinyl estradiol) and Ortho-Novum(R) 7/7/7 (norethindrone/ethinyl estradiol) a randomized clinical trial" CONTRACEPTION 2000 UNITED STATES, vol. 61, no. 5, 2000, pages 295-302, XP008050272 ISSN: 0010-7824 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007002910A1 (en) * | 2005-06-29 | 2007-01-04 | Warner Chilcott Company, Inc. | Quadraphasic continuous graduated estrogen contraceptive |
US8461138B2 (en) | 2005-06-29 | 2013-06-11 | Warner Chilcott Company, Llc | Quadraphasis continuous graduated estrogen contraceptive |
WO2007106264A2 (en) * | 2006-03-02 | 2007-09-20 | Warner Chilcott Company, Inc. | Extended cycle multiphasic oral contraceptive method |
WO2007106264A3 (en) * | 2006-03-02 | 2008-05-02 | Warner Chilcott Co Inc | Extended cycle multiphasic oral contraceptive method |
US8063030B2 (en) | 2006-03-02 | 2011-11-22 | Warner Chilcott Company, Llc | Extended cycle multiphasic oral contraceptive method |
WO2009112232A2 (en) * | 2008-03-10 | 2009-09-17 | Vladimir Hanes | New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
WO2009112232A3 (en) * | 2008-03-10 | 2010-07-22 | Vladimir Hanes | New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
US8906890B2 (en) | 2010-04-15 | 2014-12-09 | Bayer Intellectual Property Gmbh | Very low-dosed solid oral dosage forms for HRT |
US9592245B2 (en) | 2010-04-15 | 2017-03-14 | Bayer Intellectual Property Gmbh | Very low-dosed solid oral dosage forms for HRT |
Also Published As
Publication number | Publication date |
---|---|
CA2542854C (en) | 2012-04-17 |
US20110059928A1 (en) | 2011-03-10 |
US9132137B2 (en) | 2015-09-15 |
WO2005049142A3 (en) | 2005-09-29 |
CN1878558A (en) | 2006-12-13 |
EP1689411B1 (en) | 2008-10-08 |
IL174893A (en) | 2011-11-30 |
US8124595B2 (en) | 2012-02-28 |
IL174893A0 (en) | 2009-02-11 |
JP2007511533A (en) | 2007-05-10 |
US20050107351A1 (en) | 2005-05-19 |
DE602004017045D1 (en) | 2008-11-20 |
EP1689411A2 (en) | 2006-08-16 |
CA2542854A1 (en) | 2005-06-02 |
ATE410171T1 (en) | 2008-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9132137B2 (en) | Graduated estrogen contraceptive | |
CA2609336C (en) | Quadraphasic continuous graduated estrogen contraceptive | |
CA2640520C (en) | Extended cycle multiphasic oral contraceptive method | |
US5262408A (en) | Low estrogen oral contraceptives | |
CA2605299C (en) | Extended estrogen dosing contraceptive regimen | |
US7935691B2 (en) | Extended cycle multiphasic oral contraceptive kit | |
WO2021260511A1 (en) | Multiphasic contraceptive and/or hormone replacement therapy | |
MXPA06004547A (en) | Graduated estrogen contraceptive | |
MXPA06009740A (en) | Extended cycle multiphasic oral contraceptive method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480033215.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 174893 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1984/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2542854 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/004547 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006539949 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004819121 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004819121 Country of ref document: EP |